GENERATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS TYPE 3 BASED VECTORS
基于重组腺相关病毒 3 型的载体的产生
基本信息
- 批准号:10670598
- 负责人:
- 金额:$ 1.92万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 1999
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Adeno-associated viruses (AAVs) are small, non-enveloped, single-stranded DNA viruses belonging to the Porvoviridae family. AAVs have been isolated from a variety of different species, where they appear to be non-pathogenic. To date, five primate AAVs have been described, distinguished serologically by their antigenically distinct capsid proteins. Isolates of AAV-2, AAV-3 and AAV-5 have been obtained directly from human clinical specimens, and man appears to be the natural host. Until recently only AAV-2 had been characterized at the genomic level. Much of the current interest in AAVs stems from their potential use as a vector for gene therapy, with virtually all studies using AAV-2. Although AAV-2 has a broad tissue host range and can transduce a wide variety of tissue types, some cells, specifically erythroid cells have been shown to be non permissive. We have previously cloned and characterized the full-length genome of AAV-3 and produced an infectious clone. In this study, we inserted either the genes for green fluorescence protein (GFP) or beta-galactosidase into AAV-2 and AAV-3 based plasmids, and produced recombinant virus. Recombinant virus was then used to transduce hematopoietic cells, and the transduction efficiencies compared. Recombinant AAV-3 virus successfully transduced erythroid and megakaryoblastoid cells, in contrast to rAAV-2. In contrast rAAV-2 appeared better at transducing lymphocytes. These results suggest not only that there are different cellular receptors for AAV-2 and AAV-3, but that rAAV-3 vectors may be better for transduction of some hematopoietic cell types. We could also show that AAV-3 vector transduced NT2 cells in some process of differentiation, indicating that AAV-3 vectors can be used to modulate neuronal differentiation. AAV vector-mediated gene expression was persisted in the rat striatum at 7 months after injection of AAV-TH vectors.
腺相关病毒 (AAV) 是小型、无包膜、单链 DNA 病毒,属于波尔沃病毒科。 AAV 已从多种不同物种中分离出来,它们似乎不具有致病性。迄今为止,已描述了五种灵长类 AAV,通过其抗原性不同的衣壳蛋白在血清学上进行区分。 AAV-2、AAV-3 和 AAV-5 的分离株是直接从人类临床标本中获得的,而人类似乎是其天然宿主。直到最近,只有 AAV-2 在基因组水平上得到了表征。目前对 AAV 的兴趣很大程度上源于它们作为基因治疗载体的潜在用途,几乎所有研究都使用 AAV-2。尽管 AAV-2 具有广泛的组织宿主范围并且可以转导多种组织类型,但一些细胞,特别是红系细胞已被证明是不允许的。我们之前已经克隆并表征了 AAV-3 的全长基因组,并产生了感染性克隆。在这项研究中,我们将绿色荧光蛋白(GFP)或β-半乳糖苷酶的基因插入到基于AAV-2和AAV-3的质粒中,并产生重组病毒。然后使用重组病毒转导造血细胞,并比较转导效率。与 rAAV-2 相比,重组 AAV-3 病毒成功转导红细胞和巨核母细胞。相比之下,rAAV-2 似乎更擅长转导淋巴细胞。这些结果不仅表明 AAV-2 和 AAV-3 存在不同的细胞受体,而且 rAAV-3 载体可能更适合某些造血细胞类型的转导。我们还可以证明AAV-3载体在某些分化过程中转导NT2细胞,表明AAV-3载体可用于调节神经元分化。注射 AAV-TH 载体后 7 个月,AAV 载体介导的基因表达在大鼠纹状体中持续存在。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MURAMATSU Shinichi其他文献
MURAMATSU Shinichi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MURAMATSU Shinichi', 18)}}的其他基金
Gene therapy for neurodegenerative diseases using adeno-associated viral vectors that can cross the blood-brain barriers.
使用可以穿过血脑屏障的腺相关病毒载体来治疗神经退行性疾病。
- 批准号:
23590473 - 财政年份:2011
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Viral Vector Gene Therapy for Dravet Syndrome
Dravet 综合征的病毒载体基因治疗
- 批准号:
461343 - 财政年份:2022
- 资助金额:
$ 1.92万 - 项目类别:
Operating Grants
Engineering Viral Vector Biomanufacturing for Gene Therapy
用于基因治疗的工程病毒载体生物制造
- 批准号:
2602527 - 财政年份:2021
- 资助金额:
$ 1.92万 - 项目类别:
Studentship
Unravelling Genome Packaging during Recombinant AAV (rAAV) Gene Therapy Viral Vector Production
解开重组 AAV (rAAV) 基因治疗病毒载体生产过程中的基因组包装
- 批准号:
2449864 - 财政年份:2020
- 资助金额:
$ 1.92万 - 项目类别:
Studentship
Viral vector-mediated gene therapy with neuron-specific promoters for chronic pain tratment
病毒载体介导的神经元特异性启动子基因治疗用于慢性疼痛治疗
- 批准号:
20K09189 - 财政年份:2020
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Use of immunomodulatory nanoparticles in enhancing gene therapy viral vector production
使用免疫调节纳米颗粒增强基因治疗病毒载体的生产
- 批准号:
536359-2018 - 财政年份:2019
- 资助金额:
$ 1.92万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)
Development of a self-editing RNA viral vector to accelerate gene therapy for neurological diseases
开发自编辑RNA病毒载体以加速神经系统疾病的基因治疗
- 批准号:
19K22530 - 财政年份:2019
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
VectorFlow: Scalable viral vector downstream processing for gene therapy production
VectorFlow:用于基因治疗生产的可扩展病毒载体下游处理
- 批准号:
104293 - 财政年份:2018
- 资助金额:
$ 1.92万 - 项目类别:
Collaborative R&D
Generation of episomal RNA viral vector for stem cell gene therapy
用于干细胞基因治疗的游离RNA病毒载体的产生
- 批准号:
16K19069 - 财政年份:2016
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of a viral vector for gene therapy of chronic pain
开发用于慢性疼痛基因治疗的病毒载体
- 批准号:
15K15572 - 财政年份:2015
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of non-viral vector for gene therapy strategy using iPS cells
使用 iPS 细胞开发用于基因治疗策略的非病毒载体
- 批准号:
22890088 - 财政年份:2010
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Research Activity Start-up